Category Archives: Mesenchymal Stem Cells

Fayetteville, Arkansas (PRWEB) February 19, 2015 CardioWise, Inc. has completed development of the first fully integrated version of its Multiparametric Strain Analysis Software (MPSA) and has installed it at the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). MPSA software is being used in clinical research protocol number 12-H-0078, sponsored by the NHLBI entitled, Preliminary Assessment of Direct Intra-Myocardial Injection of Autologous Bone Marrow-derived Stromal Cells on Patients Undergoing Revascularization for Coronary Artery Disease (CAD) with Depressed Left Ventricular Function. The Principle Investigator is Dr. Keith A. Horvath, the Director of Cardiothoracic Surgery at the NHLBI and Chief of Cardiothoracic Surgery at Suburban Hospital, where he leads the NIH Heart Center. Details of the study are available here: http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_12-H-0078.html@mesenchymal@@@@. The recently completed integrated version of CardioWise analysis software has been installed at the NIH; and, Dr. Justin Miller, and Dr. Ming Li, both research fellows in the Cardiothoracic Surgery Research Program of the NHLBI, have been trained on its operation and use. They were assigned to the project by Dr. Horvath and Dr. Andrew Arai, Chief of the Advanced Cardiovascular Imaging Research Group in the NHLBIs Division of Intramural Research. CardioWise has completed validation testing of … Continue reading →

Dr Ellis hosts seminar on Stem Cell Therapy Facial Rejuvenation Dr. Dan Eglinton of Asheville Biologics and Orthopaedics, Dr. Sean Whalen and Dr. Paul Mogannam of Flexogenics and Dr. Laura Ellis of medAge speak about Stem Cell Therapy and skin ... By: Dr. Laura Ellis … Continue reading →

MIAMI (PRWEB) February 16, 2015 Global Stem Cells Group, Inc. announced an alliance with India-based stem cells company Advancells.com, to share protocols and expand GSCG operations in the India subcontinent with stem cell training and a new treatment center. Advancells, a pioneer stem cell company with some of the most advanced protocols in the world, focuses on therapeutic applications of regenerative medicine primarily used in stem cells generated from the patients own body. Advancells delivers technologies for safe and effective treatments using their flagship technologies including autologous stem cell therapy from bone marrow and adipose tissue to patients worldwide; Global Stem Cells Group will implement some Advancells technologies in the Regenestem Netowork of worldwide clinics. Since 2005, Advancells has safely treated thousands of patients for a range of diseases and medical conditions in its various clinics around the globe. Advancells is supported by physicians, stem cell experts and clinical research scientists to continually monitor and improve the effectiveness of its quality management system with excellence and innovation. "We are pleased to partner with Global Stem Cells Group, to combine our knowledge and expand our ability to bring stem cell medicine to patients worldwide, says Advancells CEO Vipul Jain. I am … Continue reading →

(MENAFN - ProactiveInvestors) () has been granted an ASX trading halt regarding the status of its Cymerus mesenchymal stem cell product manufacture. The halt will last until the earlier of the announcement being made or the start of trade on Thursday 19th February 2015. Its Cymerus technology enables large scale production of mesenchymal stem cells from a single one-time donor a pivotal requirement for pharmaceutical companies moving into stem cell medicine. Earlier this month it partner with the University of Western Australia to test its stem cells in lung fibrosis disease model. Proactive Investors Australia is the market leader in producing news articles and research reports on ASX Small and Mid-cap stocks with distribution in Australia UK North America and Hong Kong / China. See the article here: Cynata Therapeutics to provide status of stem cell product manufacturing technology … Continue reading →

FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEse... By: MSSocietyCanada … Continue reading →

Durham, NC (PRWEB) February 11, 2015 Stem cells collected from placenta, which is generally discarded after childbirth, show promise as a treatment for heart failure. Found in the latest issue of STEM CELLS Translational Medicine, a new study using mice determined that human-derived adherent cells (PDAC cells) significantly improved cardiac function when injected into the heart muscle. Currently, about 6 million people in the United States alone suffer from heart failure, which is when the hearts pumping power is weaker than normal. Despite intensive medical care, almost 80 percent of people die within eight years of diagnosis, making it the worlds leading cause of death. Heart failure can be the result of coronary artery disease, heart attack and other conditions such as high blood pressure and valve disease. Cell therapies for cardiac repair have generated considerable interest in recent years. While earlier studies using autologous bone marrow transplantation (that is, stem cells collected from the patients own bone marrow) helped improve cardiac function after myocardial infarction (MI), more recent studies showed no benefit in the early stages after MI. This has led researchers to question whether mesenchymal stem cells from sources other than bone marrow, such as cord blood and … Continue reading →

Stem Cells for Knee Osteoarthritis GMSCL (Guide Mesenchymal Stem Cell Layering) - For Osteoarthritis of Knee. By: Nathan Wei … Continue reading →

Biotechs may be flush with cash, thanks to the ol bullish IPO market and an uptick in venture funding. But startups remainon the lookout for alternative funding models with crowdsourcing front and center. This makes British biotech startup Cell Therapyparticularly interesting,itjustraised 689,246 or a bit over$1 million to launch a stem cell therapy for heart failure. This is one of the highest life sciences-related crowdfunding efforts topped only by Scanadu, whose handheld consumer diagnostic tool raised $1.6 million in Indiegogo. Cell Therapy, which was founded by 2007 Nobel Prize winner Martin Evans, raised the funding on thesite Crowdcube exceeding its goal of 250,000 with backing from nearly 300 investors. It ceded a mere 0.39% in equity to the backers thatinclude investment bankers, hedge fund employees and scientists, CEO Ajan Reginald said. It was very fast and very efficient, Reginaldtold Reuters. We have spent 5 percent of our time on fundraising, which enables me to spend 95 percent of my time on the business. Crowdfunding is increasingly becoming an option for early stage biotechs that want to sidestep the traditional venture-backed approach. On one hand, its a relatively simple means to raise a large amount of seed capital but on the … Continue reading →

Cell Therapy, which is based in the Welsh capital Cardiff, says the medicine has the potential to reduce scarring of the heart muscle caused by a heart attack or failure. Chief executive Ajan Reginald, who was previously at Roche, said crowd funding was a quick way to raise money for final stage trials or commercial launches. Loading article content "It was very fast and very efficient," he said. "We have spent five per cent of our time on fundraising, which enables me to spend 95 per cent of my time on the business." The company's founder Martin Evans shared the 2007 Nobel Prize for medicine for groundbreaking stem cell research. Cell Therapy used website Crowdcube to raise nearly three times its original target from more than 300 investors. Mr Reginald said the backers included investment bankers, hedge fund employees and scientists. "Crowd funding allows investors to look in detail at a company in their own time," he said, adding that some 10,000 investors had seen the pitch. The company plans to publish data from clinical trials of the drug, called Heartcel, next month, before final stage trials with a view to a launch in 2016. Originally posted here: Biotech firm … Continue reading →

* BrainStorm develops cell treatments for neurodegenerative diseases BrainStorm Cell Therapeutics Inc., a biotechnology company in Hackensack, said Monday that it has received patent approval in Israel for its NurOwn technology. NurOwn is self-transplanting adult stem-cell therapy. BrainStorm said it received a notice of allowance from Israel's Patent Office for the rights to methods of producing neurotrophic, factor-secreting cells derived from mesenchymal stem cells and methods of using those cells for the treatment of neurologic diseases. The patent is held jointly with Tel Aviv University's technology transfer company, Ramot. "This patent allowance in Israel further extends the geographic reach of our intellectual property, as we already have received similar claims in the U.S., with additional filings pending elsewhere," said BrainStorm's chief executive officer, Tony Fiorino, in a statement. BrainStorm develops adult cell therapies from bone marrow cells to treat neurodegenerative diseases. The business also has operations in Israel. Email: anzidei@northjersey.com See the original post here: Hackensack biotech company gets Israeli patent for therapy … Continue reading →